Development
Taysha Gene Therapies, Inc.
TSHA
$2.84
-$0.04-1.39%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -215.03M | -124.47M | -133.96M | -166.66M | -161.32M |
| Total Depreciation and Amortization | 1.37M | 1.32M | 1.25M | 1.17M | 1.02M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 156.69M | 55.60M | 53.99M | 58.97M | 24.73M |
| Change in Net Operating Assets | 14.34M | 14.07M | 10.66M | 17.70M | -7.79M |
| Cash from Operations | -42.62M | -53.49M | -68.07M | -88.83M | -143.36M |
| Capital Expenditure | -6.16M | -8.18M | -16.09M | -20.62M | -26.58M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.55M | -1.06M | -1.31M | -4.31M | -4.50M |
| Cash from Investing | -9.71M | -9.24M | -17.40M | -24.93M | -31.08M |
| Total Debt Issued | -- | -- | -- | -- | 9.98M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 182.89M | 42.15M | 53.34M | 53.57M | 11.96M |
| Repurchase of Common Stock | -- | -68.00K | -68.00K | -68.00K | -68.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -577.00K | -515.00K | -1.00M | -965.00K | -1.90M |
| Cash from Financing | 182.31M | 41.57M | 52.27M | 52.53M | 19.97M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 129.97M | -21.16M | -33.21M | -61.22M | -154.47M |